Reports preliminary Q4 revenue approximately $411M, consensus $407.59M. “Our strong performance this quarter reflects the continued execution of our strategy and the value our solutions deliver for customers. In 2025, we achieved a record level of incremental contract value from new customers and expanded hospital agreements with our existing customers, which positions us well for sustained performance in the year ahead,” said Katie Szyman, CEOr of Masimo (MASI).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MASI:
- Masimo’s Pediatric SpO2 Study With Philips Monitors: What Investors Should Watch
- Apple (AAPL) Cleared to Keep Importing Watch Models amid Patent Dispute
- Masimo price target raised to $190 from $187 at Wells Fargo
- Masimo price target raised to $200 from $198 at BTIG
- Masimo’s Growth Potential and Uncertainties: A Hold Rating Amidst Promising Innovations and Market Challenges